1. Home
  2. RCKT vs PMO Comparison

RCKT vs PMO Comparison

Compare RCKT & PMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCKT
  • PMO
  • Stock Information
  • Founded
  • RCKT 1999
  • PMO 1993
  • Country
  • RCKT United States
  • PMO United States
  • Employees
  • RCKT N/A
  • PMO N/A
  • Industry
  • RCKT Biotechnology: Pharmaceutical Preparations
  • PMO Finance Companies
  • Sector
  • RCKT Health Care
  • PMO Finance
  • Exchange
  • RCKT Nasdaq
  • PMO Nasdaq
  • Market Cap
  • RCKT 340.9M
  • PMO 291.4M
  • IPO Year
  • RCKT N/A
  • PMO N/A
  • Fundamental
  • Price
  • RCKT $3.03
  • PMO $10.37
  • Analyst Decision
  • RCKT Buy
  • PMO
  • Analyst Count
  • RCKT 13
  • PMO 0
  • Target Price
  • RCKT $12.88
  • PMO N/A
  • AVG Volume (30 Days)
  • RCKT 1.9M
  • PMO 99.0K
  • Earning Date
  • RCKT 11-06-2025
  • PMO 01-01-0001
  • Dividend Yield
  • RCKT N/A
  • PMO 4.10%
  • EPS Growth
  • RCKT N/A
  • PMO N/A
  • EPS
  • RCKT N/A
  • PMO 0.42
  • Revenue
  • RCKT N/A
  • PMO N/A
  • Revenue This Year
  • RCKT N/A
  • PMO N/A
  • Revenue Next Year
  • RCKT $3,582.16
  • PMO N/A
  • P/E Ratio
  • RCKT N/A
  • PMO $24.38
  • Revenue Growth
  • RCKT N/A
  • PMO N/A
  • 52 Week Low
  • RCKT $2.19
  • PMO $8.57
  • 52 Week High
  • RCKT $15.01
  • PMO $10.68
  • Technical
  • Relative Strength Index (RSI)
  • RCKT 37.29
  • PMO 51.32
  • Support Level
  • RCKT $3.10
  • PMO $10.36
  • Resistance Level
  • RCKT $3.37
  • PMO $10.45
  • Average True Range (ATR)
  • RCKT 0.20
  • PMO 0.07
  • MACD
  • RCKT -0.07
  • PMO -0.01
  • Stochastic Oscillator
  • RCKT 7.73
  • PMO 50.00

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

About PMO Putnam Municipal Opportunities Trust

Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.

Share on Social Networks: